Stock market anomaly | Mipletamig therapy achieves an 85% remission rate in leukemia patients, causing Aptevo Therapeutics (APVO.US) to soar over 130%.

According to the Zhitong Finance APP, on Wednesday, Aptevo Therapeutics (APVO.US) surged over 130%, reaching $6.52. On the news front, the company stated that its mipletamig combination therapy achieved an 85% remission rate in frontline acute myeloid leukemia patients. According to the results of the phase 1b/2 Rainer trial as described by Aptevo, mipletamig's treatment method showed strong efficacy and safety in patients not suitable for chemotherapy. The third group of the trial is nearing full enrollment at the highest dose level being tested, and the company's optimism has instilled confidence in the potential of mipletamig.